Kodiak Sciences Inc. cotiza a 97.92 USD y tiene una capitalización bursátil de $6.2B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Ph…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.94 | $-1.04 |
| Estimado | $-1.01 | $-0.96 | $-1.01 | $-1.05 |
| Sorpresa | — | — | +6.9% | +1.0% |
| Métrica | KOD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -146.1% | -40.4% | -105.7% |
| ROA | -65.4% | -32.0% | -33.4% |
| Current Ratio | 4.72 | 2.84 | +1.88 |
| Debt / Equity | — | 0.28 | — |